Printer Friendly

Amneal Names Pradeep Bhadauria as Chief Scientific Officer.

M2 PHARMA-April 3, 2019-Amneal Names Pradeep Bhadauria as Chief Scientific Officer

(C)2019 M2 COMMUNICATIONS

- US-based generic pharmaceutical manufacturer Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has appointed Pradeep Bhadauria as chief scientific officer, effective immediately, the company said.

He will succeed current CSO Dr. Shankar Hariharan, who is leaving Amneal on May 24, 2019.

Pradeep brings significant R and D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.

Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities.

Pradeep joins Amneal from Apotex, Inc., where he most recently served as executive vice president, Global R and D, responsible for leading the company's entire global R and D activities.

He also managed a large generic R and D portfolio across many dosage forms for various global markets.

Prior to joining Apotex, he served as vice president - Generic R and D for Allergan/Actavis.

Pradeep holds a Master of Pharmacy (M.Pharm) from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India. He also holds several patents and has published research in various publications.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.

The company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.

The company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders and parasitic infections.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 3, 2019
Words:331
Previous Article:MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR.
Next Article:Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters